Orchestra Life Sciences, a technical consultancy specializing in advanced therapy manufacturing solutions, plans to move its global headquarters from Montreal to Philadelphia’s Navy Yard.
“Relocating our headquarters to Philadelphia reflects both our growth as a company and our commitment to being part of this extraordinary ecosystem,” Emilie Pelletier, Orchestra Life Sciences CEO and co-founder, said. “The Navy Yard provides not only world-class infrastructure, but also the community and vision to build the workforce needed for the future of advanced therapies. We’re proud to contribute to that momentum as we help our partners deliver life-saving treatments to patients.”
Over the past three years, Orchestra has expanded from a four-person team to more than 60 employees and consultants worldwide that collectively have more than 100 years in cell and gene therapy and 500 years of nuclear medicine expertise.
Orchestra will launch a work force development program in 2026 that will provide specialized hands-on training programs for operations, quality control, and quality assurance roles in cell and gene therapy and radiopharmaceutical manufacturing. The program is intended to address a worker shortage in those fields.
Orchestra Life Sciences provides strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare diseases.